| [1] |
Siegel RL,Miller KD,Jemal A, et al. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
|
| [2] |
Chen W,Zheng R,Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [3] |
谢幸，苟文丽. 妇产科学[M]. 8版. 北京：人民卫生出版社，2013: 301.
|
| [4] |
Smith RA,Manassaram-Baptiste D,Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society Guidelines and current issues in cancer screening[J]. CA Cancer J Clin, 2015, 65(1): 30-54.
|
| [5] |
胡尚英，郑荣寿，赵方辉，等. 1989至2008年中国女性子宫颈癌发病和死亡趋势分析[J]. 中国医学科学院学报，2014, 36(2): 119-125.
|
| [6] |
Holt HK,Zhang L,Zhao FH, et al. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China[J]. Int J Cancer, 2017, 140(3): 544-554.
|
| [7] |
Al-Mandeel HM,Sagr E,Sait K, et al. Clinical practice guidelines on the screening and treatment of precancerous lesions for cervical cancer prevention in Saudi Arabia[J]. Ann Saudi Med, 2016, 36(5): 313-320.
|
| [8] |
Dijkstra MG,van Zummeren M,Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands[J]. BMJ, 2016, 355: i4924.
|
| [9] |
Schiffman M,Yu K,Zuna R, et al. Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2[J]. Int J Cancer, 2017, 140(3): 718-725.
|
| [10] |
Peirson L，Fitzpatrick-Lewis D，Ciliska D，et al. Screening for cervical cancer：a systematic review and Meta analysis[J]. Syst Rev, 2013, 2(1): 35.
|
| [11] |
Solomon D,Davey D,Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology[J]. JAMA, 2002, 287(16): 2114-2119.
|
| [12] |
孙小蓉，汪健. DNA定量细胞学[M]. 武汉：湖北科学技术出版社，2011：85-90.
|
| [13] |
Richart RM. Cervical intraepithelial neoplasia[J]. Pathol Annu, 1973, 8: 301-328.
|
| [14] |
张璐. 子宫颈脱落细胞学≥ASC-US与HPV感染、DNA倍体的研究[D]. 西宁：青海大学，2015.
|
| [15] |
贺昕红，蒋国庆，李璇. DNA倍体分析在宫颈上皮内瘤变治疗后监测的临床观察[J]. 中国计划生育和妇产科，2018, 10(8): 19-21, 29.
|
| [16] |
杨永国，丁岚. DNA倍体分析与常规细胞学诊断对宫颈上皮内瘤变的诊断价值[J]. 影像研究与医学应用，2017, 1(17): 165-166.
|
| [17] |
付蒙, 杨静，吕晓杰. DNA倍体定量分析及宫颈液基细胞学诊断宫颈上皮内瘤变[J]. 中国临床医生杂志，2017, 45(4): 77-79.
|
| [18] |
吕晓杰，曹冬如，蒋红清，等. 高危型人乳头瘤病毒负荷量与宫颈细胞DNA倍体定量关系的探讨[J]. 中国妇幼保健，2015, 30(22): 3781-3783.
|
| [19] |
Smith RA,Brooks D,Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening[J]. CA Cancer J Clin, 2013, 63(2): 88-105.
|
| [20] |
胡静，王冬芹. 液基细胞学联合人乳头瘤病毒-DNA检测在宫颈病变中的诊断价值[J/CD]. 中华妇幼临床医学杂志(电子版), 2013, 9(2): 222-224.
|
| [21] |
何玥，杨淑丽，赵群，等. 不同高危型人乳头瘤病毒检测方法在宫颈病变筛查中的应用 [J/CD]. 中华妇幼临床医学杂志(电子版), 2017, 13(4): 449-454.
|
| [22] |
李永红，毕晓芳，李晶. 细胞DNA定量分析技术在宫颈癌筛查中的应用研究[J]. 哈尔滨医药，2015, 15(6): 421-423.
|
| [23] |
夏静静. 细胞DNA分析技术及宫颈HPV检测在宫颈癌筛查中的应用[J]. 昆明：昆明医科大学，2014.
|
| [24] |
张雪梅，覃福宁，孙奇. 宫颈DNA倍体分析及TCT在宫颈病变早期筛查中的临床意义[J]. 重庆医学，2016, 45(14): 1974-1976.
|